PMID- 36320434
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230303
IS  - 2093-5552 (Print)
IS  - 2093-6214 (Electronic)
IS  - 2093-5552 (Linking)
VI  - 53
IP  - 2
DP  - 2023
TI  - COVID-19 drugs: potential interaction with ATP-binding cassette transporters 
      P-glycoprotein and breast cancer resistance protein.
PG  - 191-212
LID - 10.1007/s40005-022-00596-6 [doi]
AB  - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe 
      acute respiratory syndrome coronavirus 2, has resulted in acute respiratory 
      distress, fatal systemic manifestations (extrapulmonary as well as pulmonary), 
      and premature mortality among many patients. Therapy for COVID-19 has focused on 
      the treatment of symptoms and of acute inflammation (cytokine storm) and the 
      prevention of viral infection. Although the mechanism of COVID-19 is not fully 
      understood, potential clinical targets have been identified for pharmacological, 
      immunological, and vaccinal approaches. AREA COVERED: Pharmacological approaches 
      including drug repositioning have been a priority for initial COVID-19 therapy 
      due to the time-consuming nature of the vaccine development process. COVID-19 
      drugs have been shown to manage the antiviral infection cycle (cell entry and 
      replication of proteins and genomic RNA) and anti-inflammation. In this review, 
      we evaluated the interaction of current COVID-19 drugs with two ATP-binding 
      cassette transporters [P-glycoprotein (P-gp) and breast cancer resistance protein 
      (BCRP)] and potential drug-drug interactions (DDIs) among COVID-19 drugs, 
      especially those associated with P-gp and BCRP efflux transporters. EXPERT 
      OPINION: Overall, understanding the pharmacodynamic/pharmacokinetic DDIs of 
      COVID-19 drugs can be useful for pharmacological therapy in COVID-19 patients.
CI  - (c) The Author(s) under exclusive licence to The Korean Society of Pharmaceutical 
      Sciences and Technology 2022, Springer Nature or its licensor holds exclusive 
      rights to this article under a publishing agreement with the author(s) or other 
      rightsholder(s); author self-archiving of the accepted manuscript version of this 
      article is solely governed by the terms of such publishing agreement and 
      applicable law.
FAU - Lee, Jaeok
AU  - Lee J
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, 03760 Republic of Korea. GRID: grid.255649.9. ISNI: 0000 0001 
      2171 7754
FAU - Kim, Jihye
AU  - Kim J
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, 03760 Republic of Korea. GRID: grid.255649.9. ISNI: 0000 0001 
      2171 7754
FAU - Kang, Jiyeon
AU  - Kang J
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, 03760 Republic of Korea. GRID: grid.255649.9. ISNI: 0000 0001 
      2171 7754
FAU - Lee, Hwa Jeong
AU  - Lee HJ
AUID- ORCID: 0000-0002-8706-4810
AD  - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans 
      University, Seoul, 03760 Republic of Korea. GRID: grid.255649.9. ISNI: 0000 0001 
      2171 7754
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221026
PL  - Netherlands
TA  - J Pharm Investig
JT  - Journal of pharmaceutical investigation
JID - 101546743
PMC - PMC9607806
OTO - NOTNLM
OT  - ABC transporters
OT  - BCRP
OT  - COVID-19
OT  - COVID-19 drug
OT  - Drug-drug interaction
OT  - P-gp
COIS- Conflict of interestNone of the authors (J Lee, J Kim, J Kang and HJ Lee) have 
      potential conflicts of interest to declare.
EDAT- 2022/11/03 06:00
MHDA- 2022/11/03 06:01
PMCR- 2022/10/27
CRDT- 2022/11/02 02:08
PHST- 2022/01/27 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/11/03 06:01 [medline]
PHST- 2022/11/02 02:08 [entrez]
PHST- 2022/10/27 00:00 [pmc-release]
AID - 596 [pii]
AID - 10.1007/s40005-022-00596-6 [doi]
PST - ppublish
SO  - J Pharm Investig. 2023;53(2):191-212. doi: 10.1007/s40005-022-00596-6. Epub 2022 
      Oct 26.